Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.

Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F.

Oncologist. 2015 Feb;20(2):196-201. doi: 10.1634/theoncologist.2014-0177. Epub 2015 Jan 23. Review.

2.

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Boix-Perales H, Borregaard J, Jensen KB, Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, Schellens JH, Pignatti F.

Oncologist. 2014 Jul;19(7):766-73. doi: 10.1634/theoncologist.2013-0348. Epub 2014 Jun 13. Review.

3.

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.

4.

The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Nieto M, Borregaard J, Ersbøll J, ten Bosch GJ, van Zwieten-Boot B, Abadie E, Schellens JH, Pignatti F.

Clin Cancer Res. 2011 Nov 1;17(21):6608-14. doi: 10.1158/1078-0432.CCR-11-1734. Epub 2011 Oct 5. Review.

6.

[Clinical intervention research: two editorials and one discussion].

Jensen GB, Ersbøll J.

Ugeskr Laeger. 2005 May 23;167(21):2307-8; author reply 2308-10. Danish. No abstract available.

PMID:
15962866
7.

[Breast cancer, mammography screening and hormone therapy].

Ersbøll J.

Ugeskr Laeger. 2004 Aug 30;166(36):3113-4. Danish. No abstract available.

PMID:
15387316
8.

[Summary of product characteristics--what is it and how is it used?].

Ainsworth MA, Ersbøll J.

Ugeskr Laeger. 1999 Oct 4;161(40):5565. Danish. No abstract available.

PMID:
10553374
9.

[Trovan (trovafloxacin/alatrofloxacin) recalled: why? How?].

Stenver DI, Ersbøll J, Renneberg J.

Ugeskr Laeger. 1999 Jul 26;161(30):4311. Danish. No abstract available.

PMID:
10439701
10.

BEAM+autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single centre. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatment.

Geisler CH, Hansen MM, Andersen NS, Brown P, Christensen LD, Dickmeiss E, Ersbøll J, Myhre J, Hansen M, Juhl BR, Mortensen BT, Pedersen-Bjergaard J.

Eur J Haematol. 1998 Sep;61(3):173-82.

PMID:
9753413
11.

[Autologous stem cell transplantation. From bone marrow to selected blood stem cells: 100 consecutive procedures at a single center].

Geisler CH, Simonsen AC, Mortensen BT, Christensen LD, Ersbøll JK, Andersen NS, Dickmeiss E, Hansen MM.

Ugeskr Laeger. 1996 Apr 29;158(18):2546-51. Danish.

PMID:
8686009
12.

Histiocytic sarcomas and monoblastic leukemias. A clinical, histologic, and immunophenotypical study.

Lauritzen AF, Delsol G, Hansen NE, Horn T, Ersbøll J, Hou-Jensen K, Ralfkiaer E.

Am J Clin Pathol. 1994 Jul;102(1):45-54.

PMID:
8037167
13.
14.

Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.

Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersbøll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, et al.

Leukemia. 1993 Dec;7(12):1975-86.

PMID:
8255096
15.

Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma.

Pezzella F, Jones M, Ralfkiaer E, Ersbøll J, Gatter KC, Mason DY.

Br J Cancer. 1992 Jan;65(1):87-9.

16.

[Filgrastim--a hematopoietic growth factor (r-metHuC-CSF) for treatment of neutropenia caused by cytostatics].

Ersbøll J.

Ugeskr Laeger. 1991 Sep 16;153(38):2647-50. Danish. No abstract available.

PMID:
1719682
17.

Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.

Bork E, Ersbøll J, Dombernowsky P, Bergman B, Hansen M, Hansen HH.

J Clin Oncol. 1991 Sep;9(9):1627-31.

PMID:
1651994
18.

[Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].

Herrstedt J, Ersbøll J, Dombernowsky P.

Ugeskr Laeger. 1991 Apr 29;153(18):1292-5. Danish. No abstract available.

PMID:
1827555
19.

A simplified working formulation of non-Hodgkin's lymphomas based on quantifiable histologic criteria.

Schultz HB, Ersbøll J, Nissen NI, Hou-Jensen K.

Cancer. 1989 Dec 15;64(12):2532-40.

PMID:
2819662
20.

[Remission with antineoplastic agents?].

Ersbøll J.

Ugeskr Laeger. 1989 Jul 17;151(29):1885-6. Danish. No abstract available.

PMID:
2773106
21.

Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression.

Ersbøll J, Schultz HB, Pedersen-Bjergaard J, Nissen NI.

Eur J Haematol. 1989 Feb;42(2):155-63.

PMID:
2917634
22.

Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma.

Pedersen-Bjergaard J, Ersbøll J, Hansen VL, Sørensen BL, Christoffersen K, Hou-Jensen K, Nissen NI, Knudsen JB, Hansen MM.

N Engl J Med. 1988 Apr 21;318(16):1028-32.

PMID:
3352696
23.

Prognostic significance of differential cell counts in non-Hodgkin's lymphomas.

Schultz HB, Ersbøll J, Hougaard P.

APMIS. 1988 Apr;96(4):361-7.

PMID:
3370159
24.

[Zidovudin (Retrovir). A new antiviral agents against human immunodeficiency viruses (HIV)].

Petersen CS, Ersbøll J, Mathiesen L, Krebs HJ.

Ugeskr Laeger. 1988 Jan 25;150(4):247-8. Danish. No abstract available.

PMID:
3163864
25.

Non-Hodgkin's lymphomas: recent concepts in classification and treatment.

Ersbøll J, Schultz HB.

Eur J Haematol Suppl. 1988;48:15-29. Review. No abstract available.

PMID:
3073957
26.

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

Pedersen-Bjergaard J, Specht L, Larsen SO, Ersbøll J, Struck J, Hansen MM, Hansen HH, Nissen NI.

Lancet. 1987 Jul 11;2(8550):83-8.

PMID:
2885581
27.

Human immunodeficiency virus (HIV) associated non-Hodgkin's lymphomas in Denmark: report of three cases.

Skinhøj P, Ersbøll J, Nissen NI.

Eur J Haematol. 1987 Jul;39(1):71-4.

PMID:
3653375
28.

Application of quantifiable criteria in the Lukes and Collins classification of non-Hodgkin's lymphomas.

Schultz H, Ersbøll J.

Virchows Arch A Pathol Anat Histopathol. 1987;411(6):575-81.

PMID:
3118567
29.

Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment.

Ersbøll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI.

Scand J Haematol. 1985 Nov;35(5):487-96.

PMID:
4089528
30.

Predictive value of bone marrow cultures in 48 patients with acute myeloblastic leukaemia or myelodysplasia both secondary to treatment of other malignant diseases.

Mortensen BT, Pedersen-Bjergaard J, Tinggaard Pedersen N, Westrup M, Ersbøll J, Philip P, Nissen NI.

Scand J Haematol. 1985 Oct;35(4):423-9.

PMID:
3866312
31.

Prognostic significance of architectural patterns in non-Hodgkin lymphomas.

Schultz HB, Ersbøll J, Hougaard P.

Scand J Haematol. 1985 Sep;35(3):270-83.

PMID:
4059857
32.
34.

A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas.

Nissen NI, Ersbøll J, Hansen HS, Walbom-Jørgensen S, Pedersen-Bjergaard J, Hansen MM, Rygård J.

Cancer. 1983 Jul 1;52(1):1-7.

PMID:
6406037
35.
36.

VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.

Hansen MM, Bloomfield CD, Jørgensen J, Ersbøll J, Pedersen-Bjergaard J, Blom J, Nissen NI.

Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1135-7.

PMID:
7459900
37.

Abolished production of interferon by leucocytes of patients with the acquired cytogenetic abnormalities 5q -- or -- 5 in secondary and de-novo acute non-lymphocytic leukaemia.

Pedersen-Bjergaard J, Haahr S, Philip P, Thomsen M, Jensen G, Ersbøll J, Nissen NI.

Br J Haematol. 1980 Oct;46(2):211-23.

PMID:
6158987
38.

[Chronic lymphocytic leukemia treated with herbal remedy consisting of plant extracts].

Nissen NI, Ersbøll J, Hansen MM, Pedersen-Bjergaard J.

Ugeskr Laeger. 1979 Jul 9;141(28):1885-7. Danish. No abstract available.

PMID:
473407
39.

[The constipating effect of diphenoxylate (Retardin) in ulcerative colitis. A double-blind controlled study].

Engbaek J, Ersboll J, Faurby V, Binder V, Riss P.

Ugeskr Laeger. 1975 Apr 28;137(18):985-8. Danish. No abstract available.

PMID:
1096393
40.

The constipating effect of diphenoxylate (Retardinr) in ulcerative colitis. A double-blind controlled trial.

Engbaek J, Ersböll J, Faurby V, Binder V, Riis P.

Scand J Gastroenterol. 1975;10(7):695-8.

PMID:
1103271

Supplemental Content

Loading ...
Support Center